Canbas Co., Ltd. (4575)
JPX JPX Primary 
TWSE Summary
Canbas Co., Ltd. (4575) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Canbas Co., Ltd. ever had a stock split?
Canbas Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Takumi Kawabe M.D., Ph.D. CEO | JPX Exchange | JP3244570002 ISIN |
| Japan Country | 14 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CanBas Co., Ltd. is a clinical stage biopharmaceutical company focused on developing innovative therapeutics for cancer patients. Established in 2000, the company has positioned itself in the bio-pharmaceutical industry with a dedication to research and development, manifesting in its pioneering work on calmodulin-modulating peptides and reversible exportin-1 inhibitors. Based in Numazu, Japan, it has established a significant collaboration alliance with Stemline Therapeutics, Inc., broadening its research and market reach. CanBas is committed to advancing cancer treatment methodologies through scientific innovation and strategic partnerships.
Products and Services
- CBP501
- CBS9106
A calmodulin-modulating peptide developed by CanBas, CBP501, represents a therapeutic innovation aimed at targeting various cancers. It embodies the company's focus on groundbreaking cancer treatment solutions, leveraging biological mechanisms for effective disease management.
As a reversible exportin-1 inhibitor currently in Phase I clinical trial, CBS9106 is a testament to CanBas's commitment to exploring new frontiers in cancer treatment. Aimed at treating solid tumors, this product signifies a promising step forward in the fight against cancer through the inhibition of nuclear export signals.
